Topic: How To Invest

Q: Pat: BioLineRx is an Israeli company working in several health areas. It seems that one or more of its initiatives will succeed (of course none might). Do you have an opinion on BioLineRX? Thanks and best wishes.

Article Excerpt

A: BioLineRx (ADR), $1.18, symbol BLRX on Nasdaq (ADRs outstanding: 59.1 million; Market cap: $69.7 million; www.biolinerx.com), is a clinical-stage biopharmaceutical company that aims to identify, license and develop promising therapeutic medications and treatments. It’s based in Israel. The company licenses the new drug compounds of academic institutions and biotech companies based in Israel; it then develops them through pre-clinical and clinical stages before partnering with pharmaceutical companies. Together they work on advanced clinical development and commercialization. BioLineRx believes that its close ties with universities, research institutes, academic institutions and biotechnology companies in Israel and around the world give it access to promising projects at an early stage. Early-stage biotech firms entail considerable risk. But BioLineRx cuts that risk by partnering with major pharmaceutical companies when its therapies require significant funding. The company’s balance sheet is very sound: it has almost no debt; and it holds cash of $47.7 million, or $0.80 a share. BioLineRx also uses up its cash at a rate…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.